Inês Albuquerque - Laboratory Technician - FCT
(email@example.com)As a lab technician, Inês provided support to both Prudêncio lab and Mota lab at IMM. As the technician in charge of the cell-culture room, she maintained the hepatoma cell-lines used in the lab for experimentation and gave training to new users of this facility. As a research assistant, her work focused on the search for new antimalarial drugs, mostly against Plasmodium liver-stage infection, performing in vitro and in vivo compound screening.
Left Prudêncio lab in April 2014
Cláudia Sá e Cunha - Post-doctoral fellow - FCT
Cláudia's main research interest concerned the molecular analysis of the host components that interact with Plasmodium during a liver infection. Other projects involved the identification of new biomarkers to design diagnostic tools as well as RNAi screens to identify genes involved in a malaria liver infection, particularly those related to bile acid metabolism and nuclear receptors.
Left Prudêncio lab in September 2014
Miguel's Master's project concerned the characterization of a new malaria vaccine candidate against Plasmodium vivax using genetically modified rodent Plasmodium parasites. He presented and defended his thesis at Faculdade de Ciências de Lisboa in November 2014 and was graded 18/20.
Left Prudêncio lab in November 2014
Clemente Silva - Internship FC-UL
Left Prudêncio Lab in August 2015
Marija Markovic - Post-doctoral fellow - Bill & Melinda Gates Foundation
Marija was involved in a project towards developing a new whole-organism vaccine for malaria. Her specific goal was to find the most efficient way of producing high yields of P. berghei sporozoites in vitro, an important step in a further vaccine development. Thus, her research interest lied in understanding the parasite development in mosquito host and identification of various factors which lead to formation of infective sporozoites.
Left Prudêncio Lab in September 2015
Sarah Goellner - Internship researcher
Sarah's project investigated the impact
of a primary infection with T. brucei
on the numbers of vector-transmissible forms of both T. brucei and P. berghei in a
co-infection context with P. berghei.
Left Prudêncio Lab in September 2015
Jorge was involved in the characterization of the cellular immune responses triggered by such transgenic liver stage parasites as part of our effort to obtain a safe and efficacious pre-erythrocytic intervention strategy against malaria. He further worked on the generation, characterisation and safety assessment of a new Plasmodium strain aiming at targeting the human disease-causing blood stage parasites. Finally, he was interested in identifying the cross-species parasite antigens that are recognised by immunoglobulins of animals immunised with these vaccine candidates.
Left Prudêncio Lab in October 2015
Cláudia Marques - Post-doctoral fellow - Bill & Melinda Gates Foundation
Cláudia was involved in an international project financed by Bill and Melinda Gates Foundation: “A new whole-organism vaccine against malaria”. My main tasks are to carry out assays towards the investigation of host-parasite interactions during in vivo Plasmodium infection of animal models. In order to evaluate the efficacy of immunization/vaccination, I am responsible to perform analysis of tissues and carry out assays for the measurement of cell subset-specific cellular immune responses.
Left Prudêncio Lab in June 2016
João Sinfrónio - Master's Student @ FCUL
Left Prudêncio Lab in December 2016
Ana Margarida Vaz* - PhD Student - Lisbon BioMed
Left Prudêncio Lab in April 2021
I am a postdoctoral fellow currently working on the development of a new whole-organism vaccination strategy for Malaria. This project, supported by the Bill and Melinda Gates foundation, aims to establish live rodent Plasmodium parasites as a naturally attenuated immunizing agent capable of presenting to the human immune system a variety of antigens of human Plasmodium in a safe and physiological manner, leading to the build up of a protective responsive capable of preventing the establishment of new infections.
Left Prudêncio Lab in May 2022